ST6GALNAC6

Across TCGA pan-cancer cohorts, ST6GALNAC6 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ST6GALNAC6 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ST6GALNAC6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ST6GALNAC6 expression acts as an unfavorable survival marker.

LIHC and HNSC are the cancer types where ST6GALNAC6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.118	0.716	.003	18	view →
HNSC	OS	Median	All	0.237	0.686	.029	15	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ST6GALNAC6–LIHC (OS)

Open the LIHC breakdown →